Tags: Chemical Compound, Chemical Substance.

Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas. An oral quinoline urea derivative tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor. It was developed by AVEO Pharmaceuticals.

Tivozanib.svg
FDA UNII code
172030934T
IUPAC name
1-2-Chloro-4-[(67-dimethoxyquinolin-4-yl)oxy]phenyl-3-(5-methylisoxazol-3-yl)urea

Loading...

This page contains content from the copyrighted Wikipedia article "Tivozanib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.